Teva sales and marketing update

The FDA issued a "refuse-to-file" letter for TEVIY's NDA for Copaxone copolymer-1 to treat multiple sclerosis. The agency requested additional information on the chemistry, manufacturing and control section of the application relating to the preparation of certain reference standards and markers. ...